Newly-Named KaloBios Pharma (KBIO) CEO Shkreli Briefly Comments on Twitter About Appointment

Incoming KaloBios Pharma (NASDAQ: KBIO) CEO Martin Shkreli posted the following to Twitter late Thursday night:

Martin Shkreli, the Founder and Chief Executive Officer of Turing Pharmaceuticals AG, has acquired 70% of its outstanding shares $KBIO

— Martin Shkreli (@MartinShkreli) November 20, 2015

So happy to rescue $KBIO from having to discontinue our promising blood cancer drug lenzilumab. Let's hire the downsized employees back too!

— Martin Shkreli (@MartinShkreli) November 20, 2015

You May Also Be Interested In

• VSee Health reports revenue growth after selling VSee Lab unit
• Quantum Cyber updates shareholders on D.C. meetings and facility deal
• Cycurion alleges coordinated stock manipulation, seeks damages